After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Allogene Therapeutics Inc is $367.17M. A total of 1.5 million shares were traded on the day, compared to an average of 5.40M shares.
In the most recent transaction, Yoshiyama Annie sold 9,601 shares of ALLO for 1.41 per share on Apr 21 ’25. After the transaction, the SVP, Finance now owns 130,663 company shares. In a previous transaction on Apr 21 ’25, Yoshiyama Annie bought 9,601 shares at 1.41 per share.
Among the insiders who sold shares, Chang David D disposed of 46,668 shares on Mar 14 ’25 at a per-share price of $1.96. This resulted in the President and CEO holding 5,276,569 shares of ALLO after the transaction. In another insider transaction, Beneski Benjamin Machinas sold 5,488 shares at $1.98 per share on Mar 14 ’25. Company shares held by the SVP, Chief Technical Officer now total 218,507.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, ALLO has a high of $3.78 and a low of $1.23.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. ALLO’s latest balance sheet shows that the firm has $457.30M in Cash & Short Term Investments as of fiscal 2021. There were $73.13M in debt and $47.91M in liabilities at the time. Its Book Value Per Share was $1.99, while its Total Shareholder’s Equity was $925.20M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ALLO is Buy with a score of 4.56.
